JP2012525415A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525415A5
JP2012525415A5 JP2012508655A JP2012508655A JP2012525415A5 JP 2012525415 A5 JP2012525415 A5 JP 2012525415A5 JP 2012508655 A JP2012508655 A JP 2012508655A JP 2012508655 A JP2012508655 A JP 2012508655A JP 2012525415 A5 JP2012525415 A5 JP 2012525415A5
Authority
JP
Japan
Prior art keywords
antagonist
vegf
pdgf
administered
vegf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012508655A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032816 external-priority patent/WO2010127029A1/en
Publication of JP2012525415A publication Critical patent/JP2012525415A/ja
Publication of JP2012525415A5 publication Critical patent/JP2012525415A5/ja
Pending legal-status Critical Current

Links

JP2012508655A 2009-05-01 2010-04-28 眼科疾患を処置または予防するための方法 Pending JP2012525415A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17474609P 2009-05-01 2009-05-01
US61/174,746 2009-05-01
US17801009P 2009-05-13 2009-05-13
US61/178,010 2009-05-13
US24578409P 2009-09-25 2009-09-25
US61/245,784 2009-09-25
PCT/US2010/032816 WO2010127029A1 (en) 2009-05-01 2010-04-28 Methods for treating or preventing ophthalmological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015115569A Division JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法

Publications (2)

Publication Number Publication Date
JP2012525415A JP2012525415A (ja) 2012-10-22
JP2012525415A5 true JP2012525415A5 (https=) 2013-06-20

Family

ID=43032543

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012508655A Pending JP2012525415A (ja) 2009-05-01 2010-04-28 眼科疾患を処置または予防するための方法
JP2015115569A Pending JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法
JP2016246245A Pending JP2017081955A (ja) 2009-05-01 2016-12-20 眼科疾患を処置または予防するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015115569A Pending JP2015199749A (ja) 2009-05-01 2015-06-08 眼科疾患を処置または予防するための方法
JP2016246245A Pending JP2017081955A (ja) 2009-05-01 2016-12-20 眼科疾患を処置または予防するための方法

Country Status (7)

Country Link
US (3) US20120100136A1 (https=)
EP (3) EP3028707A1 (https=)
JP (3) JP2012525415A (https=)
AR (1) AR076523A1 (https=)
CA (1) CA2760687A1 (https=)
TW (2) TWI528963B (https=)
WO (1) WO2010127029A1 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
WO2009129546A1 (en) 2008-04-18 2009-10-22 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
KR20140044324A (ko) * 2011-04-26 2014-04-14 레가도 바이오사이언스, 인코포레이티드 페길화된 올리고뉴클레오티드의 제조방법
WO2013000909A1 (en) 2011-06-28 2013-01-03 Bayer Intellectual Property Gmbh Topical ophthalmological pharmaceutical composition containing sorafenib
KR20140048218A (ko) 2011-06-28 2014-04-23 바이엘 헬스케어 엘엘씨 레고라페닙을 함유하는 국소 안과용 약학 조성물
US20130142796A1 (en) * 2011-12-05 2013-06-06 Subhransu Ray Treatment for angiogenic disorders
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
TWI588560B (zh) 2012-04-05 2017-06-21 布萊恩荷登視覺協會 用於屈光不正之鏡片、裝置、方法及系統
JP6410710B2 (ja) 2012-04-27 2018-10-24 リアタ ファーマシューティカルズ インコーポレイテッド バルドキソロンメチルの2,2−ジフルオロプロピオンアミド誘導体、その多形体および使用方法
AU2013267310A1 (en) * 2012-06-01 2014-12-11 Ophthotech Corporation Compositions comprising an anti-PDGF aptamer and a VEGF antagonist
RS61391B1 (sr) 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
HK1204992A1 (en) 2012-06-25 2015-12-11 Bayer Healthcare Llc Topical ophthalmological pharmaceutical composition containing sunitinib
EP2863888A1 (en) * 2012-06-25 2015-04-29 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing axitinib
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
DE202013000688U1 (de) * 2012-07-03 2013-03-05 Novartis Ag Glas-Spritze
US9201250B2 (en) 2012-10-17 2015-12-01 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
HK1212194A1 (en) 2012-10-17 2016-06-10 Brien Holden Vision Institute Lenses, devices, methods and systems for refractive error
US9681805B2 (en) * 2012-11-05 2017-06-20 Babak Kamkar Afferent pupil tester
UY35183A (es) 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas
WO2014152031A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Ribonucleic acid purification
WO2014152027A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Manufacturing methods for production of rna transcripts
WO2014152030A1 (en) 2013-03-15 2014-09-25 Moderna Therapeutics, Inc. Removal of dna fragments in mrna production process
WO2014144767A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Ion exchange purification of mrna
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法
EP2994758B1 (en) 2013-05-08 2017-12-20 Opthea Limited Biomarkers for age-related macular degeneration (amd)
JP2016522249A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー 脈絡膜血管新生の治療におけるvegfアンタゴニストの使用
JP2016522248A (ja) * 2013-06-20 2016-07-28 ノバルティス アーゲー ポリープ状脈絡膜血管症の治療
EP3019527A2 (en) * 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating retinopathy of prematurity
KR20160029794A (ko) * 2013-07-11 2016-03-15 노파르티스 아게 소아 환자의 맥락망막 신생혈관성 및 투과성 장애의 치료에 있어서 vegf 길항제의 용도
SMT202100691T1 (it) 2013-07-11 2022-01-10 Modernatx Inc Composizioni 5 comprendenti polinucleotidi sintetici che codificano proteine correlate a crispr e sgrna sintetici e metodi d'uso
AU2014286996A1 (en) 2013-07-12 2016-01-07 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. 第viii因子両性イオンポリマーコンジュゲート
US20170250927A1 (en) * 2013-12-23 2017-08-31 Dali Systems Co. Ltd. Virtual radio access network using software-defined network of remotes and digital multiplexing switches
WO2015196128A2 (en) * 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2015196130A2 (en) * 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
CN108064175A (zh) * 2014-08-04 2018-05-22 米拉根医疗股份有限公司 Myh7b的抑制剂及其用途
BR112017002466A2 (pt) * 2014-08-08 2017-12-05 Forsight Vision4 Inc formulações estáveis e solúveis de inibidores da tirosina cinase do receptor, e métodos para a sua preparação
CN106852125A (zh) * 2014-08-11 2017-06-13 奥普索特克公司 用于治疗或预防眼科病的方法
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
DK3268480T3 (da) * 2015-03-09 2021-07-26 Sinai Health Sys Værktøjer og fremgangsmåder til anvendelse af celledelingsloci til at styre celleproliferation
IL298067A (en) * 2015-08-25 2023-01-01 Histide Ag Compounds for inducing tissue formation and their uses
WO2017049286A1 (en) 2015-09-17 2017-03-23 Moderna Therapeutics, Inc. Polynucleotides containing a morpholino linker
PL3350333T3 (pl) 2015-09-17 2022-03-07 Modernatx, Inc. Polinukleotydy zawierające region stabilizujący ogon
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
WO2017065559A1 (ko) * 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
KR101795650B1 (ko) 2016-05-12 2017-11-09 인제대학교 산학협력단 아플리버셉트-콜라겐 타입 ii 펩타이드의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
KR101795653B1 (ko) 2016-05-19 2017-11-09 인제대학교 산학협력단 콜라겐 타입 ii 펩타이드-아플리버셉트의 키메라 단백질을 유효성분으로 함유하는 혈관신생 억제용 조성물
WO2017223176A1 (en) 2016-06-24 2017-12-28 Modernatx, Inc. Methods and apparatus for filtration
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CN106778685A (zh) * 2017-01-12 2017-05-31 司马大大(北京)智能系统有限公司 心电图图像识别方法、装置及服务终端
CN109428697B (zh) * 2017-08-25 2021-12-28 华为技术有限公司 数据传输方法、网络设备及终端设备
CN108256457B (zh) * 2018-01-09 2021-06-04 东北大学 一种基于深度神经网络的心冲击信号深瓶颈特征提取方法
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CN108920529A (zh) * 2018-06-07 2018-11-30 北京金山安全软件有限公司 一种数据提取方法、装置及电子设备
KR20220024153A (ko) 2019-05-24 2022-03-03 엠피리코 인크. 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
CN118718181A (zh) 2019-06-05 2024-10-01 里珍纳龙药品有限公司 用于精确剂量递送的装置及方法
CN110257383B (zh) * 2019-06-24 2023-05-26 湖北师范大学 特异性识别邻苯二甲酸二(2-乙基)己酯的核酸适配体及其筛选方法与应用
CN110522902B (zh) * 2019-09-25 2022-10-11 南京农业大学 一种用于建立慢性肾病模型的组合物及其应用
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
EP4065585B1 (en) 2019-11-25 2025-08-20 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
KR102338093B1 (ko) 2021-01-14 2021-12-10 국민대학교 산학협력단 (7S)-(+)-시클로펜틸 카바믹산, 8,8-디메틸-2-옥소-6,7-디히드로-2H,8H-피라노[3,2-g]크로멘-7-일-에스테르를 유효성분으로 포함하는 안질환의 예방, 개선 또는 치료용 조성물
CN112675158A (zh) * 2021-01-26 2021-04-20 苏州市立医院 紫草醌在制备脉络膜新生血管治疗药物中的作用
IL306074A (en) 2021-03-24 2023-11-01 Alkermes Inc UPAR antibodies and fusion proteins with them
CN112852749A (zh) * 2021-03-27 2021-05-28 哈尔滨元亨生物药业有限公司 高效分泌犬细小病毒单克隆抗体杂交瘤细胞株c68及利用生物反应器对其进行生产的方法
MX2023014041A (es) 2021-05-28 2023-12-15 Shanghai Regenelead Therapies Co Ltd Virus adenoasociado recombinante que tiene una capsida variante y su aplicacion.
CN113466782B (zh) * 2021-06-08 2022-09-13 同济大学 一种基于深度学习(dl)的互耦校正doa估计方法
US20250197859A1 (en) * 2022-03-28 2025-06-19 Empirico Inc. Compositions and methods for the treatment of angiopoietin like 7 (angptl7) related diseases
KR20240163743A (ko) * 2022-03-28 2024-11-19 엠피리코 인크. 변형된 올리고뉴클레오티드
WO2023239415A1 (en) * 2022-06-08 2023-12-14 Angrow Company Limited Compositions including cannabinoid and use thereof in the manufacture of a medicament for the treatment of inflammation in a subject
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN118766879B (zh) * 2024-07-12 2025-10-10 华中科技大学 蒽醌类化合物aloesaponarin II在制备CVB3病毒抑制剂中的应用
CN118898773B (zh) * 2024-10-09 2024-12-17 江西师范大学 基于多尺度特征融合的医学图像分割方法和设备
CN121177569B (zh) * 2025-11-21 2026-02-24 重庆医科大学附属口腔医院(重庆市口腔医院) 一种感染性骨缺损仿生修复水凝胶支架及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6229002B1 (en) * 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7306799B2 (en) * 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
US20040253243A1 (en) * 2003-01-21 2004-12-16 David Epstein Aptamer therapeutics useful in ocular pharmacotherapy
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
NZ592039A (en) * 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
PL1745062T3 (pl) * 2004-04-22 2014-10-31 Regado Biosciences Inc Ulepszone modulatory czynników krzepnięcia
EP3034089A1 (en) * 2004-11-02 2016-06-22 Archemix LLC Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
AU2006213856B2 (en) * 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
PT2029746E (pt) * 2006-06-12 2012-10-15 Exegenics Inc D B A Opko Health Inc Composições e métodos para a inibição do sirna de angiogenese
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ, インコーポレイテッド 質量を削減した長時間作用剤形

Similar Documents

Publication Publication Date Title
JP2012525415A5 (https=)
JP2015528454A5 (https=)
Giddabasappa et al. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
JP2014532072A5 (https=)
CA2947067C (en) Compounds for treating ophthalmic diseases and disorders
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
JP5739908B2 (ja) 血管形成関連の眼疾患の処置のための組成物および方法
RU2015117536A (ru) Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний
JP2007503451A5 (https=)
RU2018128980A (ru) Офтальмологические составы для доставки лекарственных средств к заднему сегменту глаза
JP2010536797A5 (https=)
JP2019510078A5 (https=)
WO2016073918A1 (en) Methods for treating ocular diseases
JP2016528202A5 (https=)
AR076796A1 (es) Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento.
JP2010526780A5 (https=)
JP2013515739A5 (https=)
JP2014528700A5 (https=)
AR076523A1 (es) Metodos para tratar o prevenir enfermedades oftalmologicas. composicion.compuesto
WO2012047966A8 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
JP2014513722A5 (https=)
JP2013528563A5 (https=)
JP2018530574A5 (https=)
JP2018527327A5 (https=)
KR20140008303A (ko) 안구 혈관 질환의 치료를 위한 투여 요법